Pierre Fumoleau

Pierre Fumoleau

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

Journal: Cancer chemotherapy and pharmacology

Published: September 08, 2021

Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.

Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.

Journal: Reproductive biomedicine online

Published: June 10, 2021

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.

Journal: ESMO open

Published: March 08, 2021

Adapting to the SARS-CoV2 pandemic: Experience of the Curie Institute

Adapting to the SARS-CoV2 pandemic: Experience of the Curie Institute

Journal: Bulletin du cancer

Published: February 16, 2021

Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'.

Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'.

Journal: EBioMedicine

Published: July 11, 2020

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.

Journal: EBioMedicine

Published: March 02, 2019

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Journal: Lancet (London, England)

Published: January 20, 2019

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Journal: Contrast media & molecular imaging

Published: July 13, 2018

Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions.

Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions.

Journal: The oncologist

Published: June 15, 2018

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Journal: Breast (Edinburgh, Scotland)

Published: March 03, 2018

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response.

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 29, 2017

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.

Journal: PloS one

Published: August 02, 2017

Showing 1-12 of 148

Last Updated: 09/26/2026